Biology of chronic myeloid leukemia and its relevance to autologous bone marrow transplantation

Research output: Contribution to journalArticle

Abstract

Because of the relative resistance of chronic myeloid leukemia (CML) progenitors to most standard cytotoxic agents, marrow-ablative doses of drugs or radiotherapy followed by allogeneic bone marrow transplantation (BMT) remain the only curative option for patients with CML. However, the effectiveness of allogeneic BMT is limited by the toxicity of graft-versus- host disease and the lack of histocompatible donors for most patients. Although it avoids these major obstacles of allogeneic BMT, autologous BMT has not been effective in CML because of the inability to purge CML from the autologous graft and the absence of the allogeneic immunologic antitumor activity. Techniques that allow the clinical isolation of normal stem cells from CML marrow combined with novel posttransplantation immunotherapeutic approaches should make autologous BMT a curative treatment for CML in the near future.

Original languageEnglish (US)
Pages (from-to)122-126
Number of pages5
JournalCurrent Opinion in Oncology
Volume6
Issue number2
StatePublished - 1994

Fingerprint

Autologous Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Homologous Transplantation
Bone Marrow
Cytotoxins
Graft vs Host Disease
Radiotherapy
Stem Cells
Tissue Donors
Transplants
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research

Cite this

@article{8f7f044d20c64ab5918ba1c005046700,
title = "Biology of chronic myeloid leukemia and its relevance to autologous bone marrow transplantation",
abstract = "Because of the relative resistance of chronic myeloid leukemia (CML) progenitors to most standard cytotoxic agents, marrow-ablative doses of drugs or radiotherapy followed by allogeneic bone marrow transplantation (BMT) remain the only curative option for patients with CML. However, the effectiveness of allogeneic BMT is limited by the toxicity of graft-versus- host disease and the lack of histocompatible donors for most patients. Although it avoids these major obstacles of allogeneic BMT, autologous BMT has not been effective in CML because of the inability to purge CML from the autologous graft and the absence of the allogeneic immunologic antitumor activity. Techniques that allow the clinical isolation of normal stem cells from CML marrow combined with novel posttransplantation immunotherapeutic approaches should make autologous BMT a curative treatment for CML in the near future.",
author = "Jones, {Richard J} and Atul Bedi",
year = "1994",
language = "English (US)",
volume = "6",
pages = "122--126",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Biology of chronic myeloid leukemia and its relevance to autologous bone marrow transplantation

AU - Jones, Richard J

AU - Bedi, Atul

PY - 1994

Y1 - 1994

N2 - Because of the relative resistance of chronic myeloid leukemia (CML) progenitors to most standard cytotoxic agents, marrow-ablative doses of drugs or radiotherapy followed by allogeneic bone marrow transplantation (BMT) remain the only curative option for patients with CML. However, the effectiveness of allogeneic BMT is limited by the toxicity of graft-versus- host disease and the lack of histocompatible donors for most patients. Although it avoids these major obstacles of allogeneic BMT, autologous BMT has not been effective in CML because of the inability to purge CML from the autologous graft and the absence of the allogeneic immunologic antitumor activity. Techniques that allow the clinical isolation of normal stem cells from CML marrow combined with novel posttransplantation immunotherapeutic approaches should make autologous BMT a curative treatment for CML in the near future.

AB - Because of the relative resistance of chronic myeloid leukemia (CML) progenitors to most standard cytotoxic agents, marrow-ablative doses of drugs or radiotherapy followed by allogeneic bone marrow transplantation (BMT) remain the only curative option for patients with CML. However, the effectiveness of allogeneic BMT is limited by the toxicity of graft-versus- host disease and the lack of histocompatible donors for most patients. Although it avoids these major obstacles of allogeneic BMT, autologous BMT has not been effective in CML because of the inability to purge CML from the autologous graft and the absence of the allogeneic immunologic antitumor activity. Techniques that allow the clinical isolation of normal stem cells from CML marrow combined with novel posttransplantation immunotherapeutic approaches should make autologous BMT a curative treatment for CML in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0028343662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028343662&partnerID=8YFLogxK

M3 - Article

C2 - 8011689

AN - SCOPUS:0028343662

VL - 6

SP - 122

EP - 126

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -